J. Goldman & Co’s Axsome Therapeutics AXSM Stock Holding History

J. Goldman & Co’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,100	Closed	-$749K	–	671
2025 Q4	$749K	Buy	+4,100	New	+$572K	0.02%	422
2025 Q2	–	Sell	-34,000	Closed	-$3.97M	–	463
2025 Q1	$3.97M	Sell	34,000 -6,700	-16%	-$763K	0.1%	230
2024 Q4	$3.44M	Buy	+40,700	New	+$3.74M	0.09%	223
2024 Q1	–	Sell	-22,500	Closed	-$1.79M	–	417
2023 Q4	$1.79M	Buy	+22,500	New	+$1.5M	0.07%	195
2020 Q1	–	Sell	-30,000	Closed	-$3.1M	–	248
2019 Q4	$3.1M	Sell	30,000 -30,000	-50%	-$1.21M	0.22%	111
2019 Q3	$1.21M	Sell	60,000 -5,000	-8%	-$128K	0.09%	180
2019 Q2	$1.67M	Sell	65,000 -65,000	-50%	-$1.3M	0.12%	168
2019 Q1	$1.85M	Buy	+130,000	New	+$1.21M	0.1%	168

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's AXSM Position: Q4 2025 in Review

J. Goldman & Co sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 8,401 shares — an estimated $1.17M sold.

J. Goldman & Co first reported a position in AXSM in Q1 2019 and held it in 16 quarters. The position peaked at $4.14M in Q2 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

J. Goldman & Co reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 8,401 Axsome Therapeutics shares in Q4 2025, an estimated $1.17M.
J. Goldman & Co first reported a position in Axsome Therapeutics in Q1 2019 and held it in 16 quarters.
J. Goldman & Co's Axsome Therapeutics position peaked at $4.14M in Q2 2025.
398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.